1-2 of 2
Andrea Belschner
Close
Sort by
Journal Articles

A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome

Clinical Trials & Observations
Raffaele Badolato, Laia Alsina, Antoine Azar, Yves Bertrand, Audrey A. Bolyard, David Dale, Àngela Deyà-Martínez, Kathryn E. Dickerson, Navid Ezra, Henrik Hasle, Hyoung Jin Kang, Sorena Kiani-Alikhan, Taco W. Kuijpers, Alexander Kulagin, Daman Langguth, Carina Levin, Olaf Neth, Peter Olbrich, Jane Peake, Yulia Rodina, Caroline E. Rutten, Anna Shcherbina, Teresa K. Tarrant, Matthias G. Vossen, Christian A. Wysocki, Andrea Belschner, Gary J. Bridger, Kelly Chen, Susan Dubuc, Yanping Hu, Honghua Jiang, Sunny Li, Rick MacLeod, Murray Stewart, Arthur G. Taveras, Tina Yan, Jean Donadieu
Journal: Blood
Blood (2024) 144 (1): 35–45.
https://doi.org/10.1182/blood.2023022658
Published: 2024
Includes: Supplemental data
Journal Articles

Global Phase 3, Randomized, Placebo-Controlled Trial with Open-Label Extension Evaluating the Oral CXCR4 Antagonist Mavorixafor in Patients with WHIM Syndrome (4WHIM): Trial Design and Enrollment

David C. Dale, Laia Alsina, Antoine Azar, Raffaele Badolato, Ashish Bhandari, Andrea Belschner, Yves Bertrand, Diego Cadavid, Kathryn E. Dickerson, Navid Ezra, Henrik Hasle, Harold Hoffman, Honghua Jiang, Hyoung Jin Kang, Sorena Kiani-Alikhan, Taco W. Kuijpers, Aleksandr D. Kulagin, Daman Langguth, Carina Levin, Richard MacLeod, Olaf Neth, Jane Peake, Yulia Rodina, Anjali Sharathkumar, Anna Shcherbina, Weihua Tang, Matthias G. Vossen, Jean Donadieu
Journal: Blood
Blood (2021) 138 (Supplement 1): 4310.
https://doi.org/10.1182/blood-2021-153346
Published: 2021